Log in
Sign up
Amicus Therapeutics

Amicus Therapeutics

Amicus Therapuetics is a biotechnology company developing therapies to cure rare diseases.

OverviewStructured DataIssuesContributorsActivity
Contents

Amicus Therapeutics is a publicly listed biotechnology company focused on the discovery, development, and delivery of treatments for rare metabolic diseases. Headquartered in New Jersey, the company also operates officers internationally. They include the UK, Canada, Japan, Germany, France, Italy, The Netherlands, Spain, and Australia.

Products
Medication for Fabry disease

Amicus' developments include one commercialized medication for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and several gene therapy pipeline and growth platform for lysosomal storage disorders, including Batten Disease, Neimann-Pick Type C, Wolman Disease, and Tay Sachs.

In August 2018, the US FDA approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare and sometime fatal condition in which accumulation of fat damages several organs. It is a long-term treatment for adult patients with specific genetic mutations, which account for an estimated 35 to 50% of diagnosed cases globally. Chemically known as migalastat, the drug has also been approved in Europe, Japan, Australia, and Canada.

Medication for Pompe disease

The company's investigational therapy, AT-GAA, for Pompe disease, an inherited Lysosomal Storage (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), completed a Phase 2 safety and pharmacokinetics study in 2013.

Gene Therapy for Batten disease

Amicus is also conducting multiple Phase 1/2 studies for their CLN6 gene therapy to treat Batten disease, a broad class of rare, fatal, inherited disorders of the nervous system known as neuronal ceroid lipofuscinoses (NCLs).

Funding
Series A

On July 25, 2002 Amicus Therapeutics completed their series A funding round with $2 million in funding from CHL Medical Partners.

Series B

On May 13, 2004 Amicus Therapeutics completed their series B funding round with $31 million in funding from Canaan Partners (lead investor), Radius Venture Partners, New Enterprise Associates, Frazier Healthcare Partners, and CHL Medical Partners.

Series C

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners.

Timeline

No Timeline data yet.

Funding Rounds

Open in Query Tool

Products

Open in Query Tool

Acquisitions

Open in Query Tool

SBIR/STTR Awards

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Robin Respaut

https://www.reuters.com/article/us-amicus-fda/amicus-therapeutics-receives-u-s-approval-for-fabry-disease-drug-idUSKBN1KV2D5

Web

References

amicusrx.co.uk
amicusrx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Engineering
Engineering
Pharmaceutical industry
Pharmaceutical industry
Healthcare
Healthcare
Biopharmaceutical
Biopharmaceutical
Therapeutics
Therapeutics
Drug discovery
Drug discovery
Therapy
Therapy
...
Location
Philadelphia
Philadelphia
-1
United Kingdom
United Kingdom
Cranbury (CDP), New Jersey
Cranbury (CDP), New Jersey
New York
New York
United States
United States
Cranbury, New Jersey
Cranbury, New Jersey
Dublin
Dublin
-1
Paris
Paris
-1
...
B2X
B2B
B2B
Founder
John Crowley
John Crowley
-1
AngelList URL
angel.co/amicus-therapeutics
Pitchbook URL
pitchbook.com/profiles.../42020-56
Legal Name
Amicus Therapeutics, Inc.
Date Incorporated
February 4, 2002
Number of Employees (Ranges)
201 – 500
Full Address
Regus Dublin, Blanchardstown Block 1, Blanchardstown Corporate Park Ballycoolin Road Blanchardstown, Dublin 15 Ireland D15 AKK1-1
Bahnhofstrasse 100 8001 Zürich Schweiz-1
6500 Trans-Canada Road, 4th Floor Pointe-Claire, Québec H9R 0A5-1
Willy-Brandt-Platz 3 81829 München, Germany-1
3675 Market Street Philadelphia, PA 19104-1
Paseo de la Castellana, 55, planta 1 28046 Madrid-1
One Globeside Fieldhouse Lane Marlow SL7 1HZ United Kingdom-1
Opéra E, Les Collines de l’Arche, 76 route de la Demi-Lune, 92057 Paris La Défense Cedex, France-1
...
CIK Number
1,178,879-1
Place of Incorporation
Delaware
Delaware
-1
Investors
Quaker BioVentures
Quaker BioVentures
Tribe Capital
Tribe Capital
-1
Palo Alto Investors (company)
Palo Alto Investors (company)
Radius Ventures
Radius Ventures
Frazier Healthcare Partners
Frazier Healthcare Partners
‌
CareCapital
-1
DUNS Number
124322095-1
IRS Number
200,422,823-1
Founded Date
2002
Email Address
info@amicusrx.com-1
info@amicusrx.nl-1
info@amicusrx.it-1
info@amicusrx.fr-1
info@amicusrx.es-1
info@amicusrx.de-1
info@amicusrx.co.uk-1
medinfoaustralia@amicusrx.com-1
...
Phone Number
+12159217600-1
+11300264287-1
+33172757254-1
+41445627098-1
+81352191490-1
+34917376973-1
+390291577454-1
+4989248879810-1
...
Total Funding Amount (USD)
18,582,360
Latest Funding Round Date
July 30, 2012
Competitors
Audentes Therapeutics
Audentes Therapeutics
Interius BioTherapeutics
Interius BioTherapeutics
Stock Symbol
FOLD-1
Exchange
Nasdaq
Nasdaq
-1
Glassdoor ID
26068
Board of Directors
Michael Raab (entrepreneur)
Michael Raab (entrepreneur)
-1
John Crowley
John Crowley
‌
Lynn D. Bleil
-1
‌
Margaret G. McGlynn
-1
‌
Robert Essner
-1
‌
Eiry W. Roberts
-1
Burke W. Whitman
Burke W. Whitman
-1
Glenn P. Sblendorio
Glenn P. Sblendorio
-1
...
CFO
‌
Daphne Quimi
NAICS Code
325,412-1
CAGE Code
603U6-1
Patents Assigned (Count)
105
COO
‌
Bradley L. Campbell
Wellfound ID
amicus-therapeutics
Country
Canada
Canada
-1
Germany
Germany
-1
Italy
Italy
-1
Republic of Ireland
Republic of Ireland
-1
Japan
Japan
-1
Netherlands
Netherlands
-1
Portugal
Portugal
-1
Spain
Spain
-1
...
Headquarters
Philadelphia
Philadelphia
-1

Other attributes

Company Operating Status
Active
Previous Name
AMICUS THERAPEUTICS INC-1
SIC Code
2,834-1
Ticker Symbol
FOLD-1
Wikidata ID
Q18636342

Find more companies like Amicus Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.